February 16th 2024
The FDA has approved lifileucel, a tumor infiltrating lymphocyte therapy, for the treatment of advanced melanoma.
December 19th 2023
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
CMS Tackles Drug Prices, But What Does This Mean for Patient Care Access?
October 19th 2018Rising prescription drug prices continue to add to the burden of paying for quality healthcare. In an effort to confront such costs, the Centers for Medicare & Medicaid Services has rescinded a prohibition on step therapy for Medicare Advantage plans. But some contend such a policy will reduce patient access to optimal medication.
Read More
Immunotherapy Pioneers Allison, Honjo Awarded Nobel Prize
October 1st 2018James P. Allison, PhD, and Tasuku Honjo, MD, PhD, have been awarded the 2018 Nobel Prize in Physiology or Medicine for their pioneering research that led to the use of immune checkpoint inhibitors in the treatment of cancer. The award was announced in a statement from the Nobel Assembly at Karolinska Institutet on Monday.
Read More
Cemiplimab Approved by FDA for CSCC
September 29th 2018Cemiplimab (Libtayo) has been approved by the FDA for the treatment of patients with metastatic cutaneous squamous cell carcinoma or patients with locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Read More
European Commission Approves BRAF/MEK Combination for BRAF+ Melanoma
September 21st 2018According to an announcement from Array BioPharma, the company developing the regimen, the European Commission approved the combination of encorafenib, a BRAF inhibitor, and binimetinib, a MEK inhibitor, for treatment of adult patients with <em>BRAF</em> V600–mutant unresectable or metastatic melanoma.
Read More
Expert Highlights Significance of BRAF/MEK Findings, Ongoing Research in Melanoma
September 11th 2018Paolo A. Ascierto, MD, discusses results from the COLUMBUS trial and sheds light on how physicians can use these findings when choosing treatments for their patients. He also shared his insights on the CheckMate 238 trial investigating nivolumab in the adjuvant setting.
Read More
Combining HDAC Inhibitors With Immunotherapy in Melanoma
September 7th 2018Sanjiv S. Agarwala, MD, chairman of medical oncology at St. Luke’s University Health Network, discusses the combination of immunotherapy and a histone deacetylase inhibitor in patients with melanoma, as well as other types of cancer.
Watch
Flaherty Highlights Best-In-Class Findings With BRAF/MEK Inhibitor Combo in Melanoma
September 6th 2018Keith T. Flaherty, MD, discusses results for the combination of encorafenib and binimetinib in patients with <em>BRAF</em>-mutated melanoma investigated in the COLUMBUS trial. He also highlights the potential implications and next steps.
Read More
Europe Approves Adjuvant Dabrafenib/Trametinib for BRAF+ Melanoma
August 30th 2018The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) has gained approval from the European Commission for the adjuvant treatment of patients with <em>BRAF </em>V600–positive stage III melanoma following complete resection.
Read More
Expert Details "Intriguing" Findings With Entinostat/Pembrolizumab Combo in Advanced Melanoma
August 15th 2018Sanjiv S. Agarwala, MD, discusses the promising activity seen with the combination of pembrolizumab and entinostat in patients with advanced melanoma, according to initial results from the ongoing ENCORE 601 trial.
Read More
Rationale for MEK/BRAF Combinations in Melanoma
August 15th 2018Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses the rationale for combining agents like dabrafenib with trametinib or binimetinib with encorafenib for patients with melanoma.<br />
Watch
Adjuvant Nivolumab Gains European Approval for Melanoma
August 1st 2018Adjuvant nivolumab has been approved by the European Commission as a treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease, regardless of <em>BRAF</em> mutation status, based on findings from the randomized phase III CheckMate-238 trial.
Read More
Older Age Correlates With Better Response to Anti-PD-1 Therapy in Melanoma
July 18th 2018Patients aged ≥62 years with melanoma were more likely to respond to treatment with pembrolizumab than younger patients, according to results published in <em>Clinical Cancer Research. </em>Investigators at The Wistar Institute in Philadelphia concluded that the risk for progression following anti–PD-1 therapy declined by 13% with each decade of life.
Read More
Analysis Shows Incidence of Cardiovascular Toxicities Associated With ICIs
July 3rd 2018Immune checkpoint inhibitors, alone or in combination, are associated with increased incidence of some cardiovascular toxicities in patients with cancer, according to results from a cross-trial pooled analysis presented in a poster at the 2018 ASCO Annual Meeting.
Read More